GlassScriptPhysician profile
Randy Almanzar
NPI 1386991420
$4,060.34
in general payments reported to CMS, 2019-2025
32 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $994 · 2021: $458 · 2022: $37.08 · 2023: $138 · 2024: $485 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $872.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $824.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $511.21 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $292.43 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.40 | 2019-2025 | Jardiance |
| Allergan, INC. | $128.69 | 2019 | |
| Astellas Pharma US INC | $110.02 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $93.25 | 2019-2021 | |
| Amarin Pharma, INC. | $89.64 | 2019-2021 | |
| Medtronic, INC. | $81.56 | 2023 | Corevalve Evolut R |
| Arbor Pharmaceuticals, INC. | $79.40 | 2019-2020 | |
| Abbvie INC. | $70.33 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $65.81 | 2020-2024 | Zoryve |
| Amgen INC. | $64.98 | 2024-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.86 | 2020-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.14 | 2021-2025 | |
| Abbott Laboratories | $60.01 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $55.46 | 2019-2021 | |
| Glaxosmithkline, LLC. | $51.02 | 2019-2021 | |
| Hologic Sales and Service, LLC | $38.62 | 2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $35.53 | 2025 | |
| Axsome Therapeutics, INC. | $35.25 | 2025 | Auvelity |
| Boston Scientific Corporation | $29.80 | 2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $27.96 | 2019-2020 | |
| Eisai INC. | $25.51 | 2021 | |
| Exact Sciences Corporation | $24.79 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $20.62 | 2020 | |
| Lundbeck LLC | $15.99 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $15.88 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $13.73 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.61 | 2021 | |
| Sanofi Pasteur INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Almanzar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.